Daiichi Sankyo

Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks
Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks
Fierce Biotech
Daiichi Sankyo
immuno-oncology
Zymeworks
bispecific antibodies
Flag link:
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
Yahoo/Reuters
AstraZeneca
Daiichi Sankyo
breast cancer
trastuzumab deruxtecan
Flag link:
Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit
Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit
Fierce Biotech
R&D
Daiichi Sankyo
Flag link:
Daiichi gets speedy FDA review for rare cancer drug
Daiichi gets speedy FDA review for rare cancer drug
Pharmaforum
Daiichi Sankyo
FDA
pexidartinib
TGCT
priority review
Flag link:
Daiichi Sankyo takes option on diabetes stem cell start-up
Daiichi Sankyo takes option on diabetes stem cell start-up
Pharmaforum
Daiichi Sankyo
stem cells
Tokyo Institute of Technology
type 1 diabetes
OiDE BetaRevive
Flag link:
Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market
Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market
Endpoints
Daiichi Sankyo
Esperion Therapeutics
Flag link:
Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer
Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer
Pharmaceutical Business Review
Daiichi Sankyo
Merck
Pfizer
clinical trials
DS-8201
solid tumors
Flag link:
Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC
Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC
Pharmaceutical Business Review
Daiichi Sankyo
non-small cell lung cancer
DS-1205
Flag link:
Encouraging trial results for Daiichi anti-stroke therapy
Encouraging trial results for Daiichi anti-stroke therapy
The Pharma Letter
Daiichi Sankyo
Lixiana
edoxaban
clinical trials
atrial fibrilation
stroke
Flag link:
Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug
Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug
Fierce Biotech
Novartis
Rydapt
acute myeloid leukemia
Daiichi Sankyo
quizartinib
Flag link:
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Endpoints
Daiichi Sankyo
Duchenne Muscular Dystrophy
DS-5141
Flag link:
Could This be the End of Flu Shots?
Could This be the End of Flu Shots?
CP Wire
Vaxart
influenza vaccines
Daiichi Sankyo
vaccines
oral vaccines
Flag link:
Could This be the End of Flu Shots? - Updated
Vaxart
influenza vaccines
Daiichi Sankyo
Flag link:
Top 5 boards for week ending March 10, 2018
Top 5 boards for week ending March 10, 2018
CP Wire
Daiichi Sankyo
Shire
Amgen
Sanofi
AstraZeneca
Flag link:
3 Things In Biotech, March 8: A Tale Of 3 New Trials
3 Things In Biotech, March 8: A Tale Of 3 New Trials
Seeking Alpha
biotech
clinical trials
Seattle Genetics
SGN-CD48A
Daiichi Sankyo
DS-8201
HER-positive colorectal cancer
Allena Pharmaceuticals
hyperoxaluria
Flag link:
Top 5 viewed boards for week ending March 3, 2018
Top 5 viewed boards for week ending March 3, 2018
CP Wire
cafepharma
Daiichi Sankyo
Shire
Allergan
Amgen
Sanofi
sales meeting
layoffs
Esmya
Pfizer
Celgene
M&A
Flag link:
Daiichi Sankyo douses a report about an AstraZeneca buyout offer
Daiichi Sankyo douses a report about an AstraZeneca buyout offer
Endpoints
AstraZeneca
Daiichi Sankyo
M&A
Flag link:
Daiichi Sankyo punts $650M collaboration pact as Charleston Labs preps a comeback attempt on spurned pain drug
Daiichi Sankyo punts $650M collaboration pact as Charleston Labs preps a comeback attempt on spurned pain drug
Endpoints
Daiichi Sankyo
Charleston Laboratories
CL-108
painkillers
Flag link:
Daiichi Sankyo hands off cancer drug to Boston Pharma
Daiichi Sankyo hands off cancer drug to Boston Pharma
BioPharma Dive
Boston Pharmaceuticals
Daiichi Sankyo
DS-5010
cancer
Flag link:
Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar
Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar
Reuters
Daiichi Sankyo
Benicar
Flag link:

Pages